MYRIAD GENETICS INC (MYGN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 80M 160M 240M Q3 '21: 167.3M Q4 '21: 160.8M Q1 '22: 164.9M Q2 '22: 179.3M Q3 '22: 156.4M Q4 '22: 177.8M Q1 '23: 181.2M Q2 '23: 183.5M Q3 '23: 191.9M Q4 '23: 196.6M Q1 '24: 202.2M Q2 '24: 211.5M Q3 '24: 213.3M Q4 '24: 210.6M Q1 '25: 195.9M Q2 '25: 213.1M Q3 '25: 205.7M Q4 '25: 209.8M Q1 '26: 200.4M Q2 '26: 190.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 60M 120M 180M Q1 '24: 137.6M Q2 '24: 147.1M Q3 '24: 149.8M Q4 '24: 150.9M Q1 '25: 134.2M Q2 '25: 151.8M Q3 '25: 143.8M Q4 '25: 146.8M Q1 '26: 137.6M Q2 '26: 127M Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Income Quarterly

-450M -300M -150M 0 150M 300M 450M Q3 '21: -79.9M Q4 '21: -43.1M Q1 '22: -25.6M Q2 '22: -17.8M Q3 '22: -45M Q4 '22: -52.2M Q1 '23: -52.2M Q2 '23: -113.7M Q3 '23: -60.1M Q4 '23: -31.4M Q1 '24: -27.9M Q2 '24: -36.5M Q3 '24: -20M Q4 '24: -39M Q1 '25: -29M Q2 '25: -329.2M Q3 '25: -23.3M Q4 '25: -5.7M Q1 '26: -30.7M Q2 '26: -38.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-450M -300M -150M 0 150M 300M 450M Q3 '21: 24.6M Q4 '21: -7.6M Q1 '22: -20.5M Q2 '22: -14.1M Q3 '22: -35.1M Q4 '22: -42.3M Q1 '23: -54.7M Q2 '23: -116.1M Q3 '23: -61.3M Q4 '23: -31.2M Q1 '24: -26M Q2 '24: -36.7M Q3 '24: -22.1M Q4 '24: -42.5M Q1 '25: -100K Q2 '25: -330.5M Q3 '25: -27.4M Q4 '25: -7.9M Q1 '26: -34.1M Q2 '26: -43.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 25M 50M 75M Q4 '17: 37.7M Q1 '18: 36.8M Q1 '22: 48M Q2 '22: 49.7M Q3 '22: 50.4M Q4 '22: 53.9M Q1 '23: 59.2M Q2 '23: 57.8M Q3 '23: 57.6M Q4 '23: 61.6M Q1 '24: 64.6M Q2 '24: 64.4M Q3 '24: 63.5M Q4 '24: 59.7M Q1 '25: 61.7M Q2 '25: 61.3M Q3 '25: 61.9M Q4 '25: 63M Q1 '26: 62.8M Q2 '26: 63.7M Q1 '18 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -39.3M Q4 '21: -9.5M Q1 '22: -46.5M Q2 '22: -49.7M Q3 '22: -2.8M Q4 '22: -7.3M Q1 '23: -33.2M Q2 '23: -900K Q3 '23: -22.1M Q4 '23: -54.7M Q1 '24: -18.6M Q2 '24: 2.6M Q3 '24: 700K Q4 '24: 6.6M Q1 '25: -16.3M Q2 '25: -13.6M Q3 '25: 21.1M Q4 '25: 10.6M Q1 '26: -15.7M Q2 '26: -8.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -42.3M Q4 '21: -12.9M Q1 '22: -52.8M Q2 '22: -56.4M Q3 '22: -20.5M Q4 '22: -21.9M Q1 '23: -56.7M Q2 '23: -19.7M Q3 '23: -33M Q4 '23: -64.7M Q1 '24: -25.3M Q2 '24: -2.6M Q3 '24: -2.8M Q4 '24: 3M Q1 '25: -21.6M Q2 '25: -16.4M Q3 '25: 18.3M Q4 '25: 5.9M Q1 '26: -21.1M Q2 '26: -10.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '20: 74.6M Q3 '20: 74.7M Q4 '20: 75.3M Q1 '21: 76M Q2 '21: 77.2M Q3 '21: 81.5M Q1 '22: 80.1M Q2 '22: 80.4M Q3 '22: 80.7M Q1 '23: 81.3M Q2 '23: 81.7M Q3 '23: 81.9M Q1 '24: 89.9M Q2 '24: 90.6M Q3 '24: 90.9M Q1 '25: 91.4M Q2 '25: 92.5M Q3 '25: 93.1M Q1 '26: 93.7M Q2 '26: 94.8M Q3 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '21: -0.78 Q4 '21: -0.35 Q1 '22: -0.09 Q2 '22: -0.21 Q3 '22: -0.94 Q4 '22: -1.39 Q1 '23: -1.80 Q2 '23: -3.04 Q3 '23: -3.36 Q4 '23: -3.18 Q1 '24: -2.80 Q2 '24: -1.79 Q3 '24: -1.28 Q4 '24: -1.41 Q1 '25: -1.12 Q2 '25: -4.28 Q3 '25: -4.33 Q4 '25: -3.93 Q1 '26: -4.29 Q2 '26: -1.18 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.